Transcatheter closure of apical ventricular muscular septal defect combined with arterial switch operation in a newborn infant

Rodés, Josep; Piéchaud, Jean François; Ouaknine, Ruth; Hulin, Sylvie; Cohen, Laurence; Magnier, S; Lecompte, Y; Lefèvre, Thierry

doi:10.1002/(sici)1522-726x(200002)49:2<173::aid-ccd12>3.0.co;2-q

Cited by 18 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative closure of muscular VSDs in advance of complex heart surgery for associated lesions contributes to decreased morbidity and perhaps mortality. Hybrid interventions, which are in this context defined as percutaneous device closure of a VSD in the cath lab or in the operating room immediately before reconstructive surgery, are possible even in the newborn period 16 and should be considered. Percutaneous or intraoperative positioning of the device can avoid ventriculotomy 19 .…”

Section: Discussionmentioning

confidence: 99%

“…3,[6][7][8][9] With the development of the self-centering Amplatzer devices, an increasing number of defects could be closed first in the muscular septum [10][11][12] and recently in the membranous septum with specially designed asymmetric occlusion devices to prevent regurgitation of the tricuspid or aortic valve. [13][14][15] Hybrid therapy in the treatment of congenital heart disease that involves complex surgery together with transcatheter closure of the VSDs has been described in the literature 4,[16][17][18][19] and offers the chance to decrease morbidity and mortality. This study describes the experience of transcatheter VSD closure with special consideration of the location of the VSD and the appropriate closing device.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Closure of Congenital and Acquired Ventricular Septal Defects—Considerations on Selection of the Occlusion Device

Michel‐Behnke¹,

Lê²,

Waldecker³

et al. 2005

J Interven Cardiology

View full text Add to dashboard Cite

Nonsurgical closure of congenital and acquired ventricular septal defects (VSD) has become increasingly acceptable with the availability of various occlusion systems that allow percutaneous treatment of muscular and membranous defects. This study describes a series of 12 patients (0.2–74‐years‐old) who underwent defect closure with six different occlusion systems. Device selection according to anatomy and outcome is highlighted. Seven VSDs were located in the membranous part of the septum, five in the mid‐muscular septum. Complex heart lesions were present in five postmyocardial infarction VSD in one and residual postsurgical defects in three patients. The size of the VSD ranged from 2.6 to 10 mm. The applied devices were: Amplatzer muscular VSD occluder (n = 4), Amplatzer septal occluder (n = 2), Amplatzer duct occluder (n = 1), Amplatzer membranous VSD occluder (n = 2), Nit‐Occlud coil (n = 2), and Cook PDA coil (n = 1). The devices were implanted successfully in nine patients. There was complete VSD closure in eight patients within the first 24 hours. In one patient, a trivial residual shunt disappeared at 6 months follow‐up. Because of device instability, two occluders were removed during catheterization. In two other cases, tricuspid valve tissue was entrapped in the occluder and had to be removed surgically, one of them during the consecutive Rastelli operation. Neither significant arrhythmia, nor thromboembolism or hemolysis occurred in out patients during follow‐up. Transcatheter closure of VSD is an attractive alternative to surgery. In complex congenital heart disease, surgical‐interventional hybrid therapy may improve morbidity and total outcome. The recently developed Amplatzer VSD devices allow closure of muscular and membranous VSDs. Implantation and short‐term follow‐up are superior to the formerly used devices. Long‐term effects have to be evaluated in further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Percutaneous Closure of Congenital and Acquired Ventricular Septal Defects—Considerations on Selection of the Occlusion Device

Michel‐Behnke¹,

Lê²,

Waldecker³

et al. 2005

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…In the last decade, with the availability of various newer devices and improvement in imaging techniques, especially various modalities of echocardiography (two‐dimensional, three‐dimensional, and intracardiac); percutaneous transcatheter closure of intracardiac defects has considerably improved either as a treatment of choice or palliation or complementary to operative procedures 14,15 . The advantages compared to surgery are the avoidance of morbidity related to thoracotomy and cardiopulmonary bypass; also, the length of hospital stay is much shorter, most often general anesthesia is not necessary and for some high‐risk patients this is the only therapeutic option.…”

Section: Discussionmentioning

confidence: 99%

“…Morever, there is a higher incidence of postsurgical residual shunt requiring reoperation. Not only is catheter closure being preferred for these residual shunts, but it is also being utilized as an adjunct to surgery in complex cyanotic congenital heart disease 14,15 . This report describes the initial and long‐term results of catheter closure of congenital muscular VSD using various devices.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter Closure of Congenital Muscular Ventricular Septal Defect

Arora

Trehan

Thakur

et al. 2004

J Interven Cardiology

View full text Add to dashboard Cite

The success with occlusion devices for the closure of atrial septal defects and patent ductus arteriosus prompted the transcatheter closure of single and multiple muscular ventricular septal defects (VSD). The procedure for VSD was first attempted by Lock et al. in 1988 and devices originally designed for the closure of other intracardiac defects (Rashkind umbrella device, Lock clamshell, Cardioseal, coils, Sideris buttoned device etc.) were used with a variable success rate and a residual shunt. Recently, specially designed Amplatzer muscular VSD occluder and Sideris device are in use. The Amplatzer muscular VSD occluder has been undergoing clinical trial since 1998 after the animal experiments had shown 100% occlusion and complete endothelization at 3 months. The procedure was first attempted in August 1995 using the Rashkind umbrella device and since April 1998 only the Amplatzer muscular VSD occluder has been used. Of the149 patients who underwent transcatheter closure of VSD, 50 had muscular trabecular defects in various locations: mid-muscular, anterior, posterior, or apical. All cases were selected by detailed transthoracic and/or transesophageal echocardiography (TTE) and aneurysm of the muscular septum was observed in three of them. The age range was 3-28 years and the diameter of VSD was 4-11 mm. In all but one patient, the device was deployed from the venous side. Simultaneous TTE was done for proper positioning of the device and continuous electrocardiographic monitoring was also done for any arrhythmia/conduction defects. All patients were followed up every 3 months and received 3-5 mg/kg aspirin for 6 months. The procedure was successful in all patients. The Rashkind umbrella device (17 mm) was used in two and Amplatzer muscular VSD occluder (6-14 mm) in 48 patients. Forty-four devices were delivered by antegrade transvenous approach and six by the transjugular route. None had residual shunt, new aortic regurgitation, or tricuspid regurgitation. Transient complete heart block after 24 hours was noticed in one patient. On a follow-up of 2-90 months, the device was in position in all patients. There was no embolization of the device, and no late-conduction defects, infective endocarditis, or hemolysis. Transcatheter closure of muscular VSD is safe and efficacious, and should be considered as a procedure of choice as an alternative to surgery that avoids cardiopulmonary bypass.

show abstract

“…The first percutaneous VSD closure has been described by Lock et al in 1988 [6]. Since then, various attempts have been made to close VSDs by using Rashkind umbrellas, Clamshell, Cardioseal, Starflex, Sideris buttoned devices and Gianturco coils [6–21]. But so far results have not been satisfactory.…”

Section: Introductionmentioning

confidence: 99%

Preclinical evaluation of a new self‐expanding device for closure of muscular ventricular septal defects in a pig model

Lang

Schmitz

Lehner

et al. 2009

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Transcatheter closure of apical ventricular muscular septal defect combined with arterial switch operation in a newborn infant

Cited by 18 publications

References 14 publications

Percutaneous Closure of Congenital and Acquired Ventricular Septal Defects—Considerations on Selection of the Occlusion Device

Percutaneous Closure of Congenital and Acquired Ventricular Septal Defects—Considerations on Selection of the Occlusion Device

Transcatheter Closure of Congenital Muscular Ventricular Septal Defect

Preclinical evaluation of a new self‐expanding device for closure of muscular ventricular septal defects in a pig model

Contact Info

Product

Resources

About